Human Genome Sciences
reported a narrower-than-expected loss for the third quarter, beating analysts' estimates by a penny.
The Rockville, Md., biotechnology company lost $13 million, or 12 cents a share, excluding a one-time write-off related to an acquisition in September. In the same period a year ago, Human Genome lost $9.7 million, or 11 cents a share. Twelve analysts expected the company to lose 13 cents a share for the quarter, according to
First Call/Thomson Financial
Total revenue for the quarter rose to $8.1 million from $7.4 million for the year-ago period.